Cargando…

Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)

PURPOSE: To assess the incremental burden of corneal transplant surgery for US commercially insured patients with Fuchs endothelial corneal dystrophy (FECD) treated with endothelial keratoplasty (EK) compared to controls. METHODS: The study design was retrospective cohort using IBM(®) MarketScan(®)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhaliwal, Deepinder K, Chirikov, Viktor, Schmier, Jordana, Rege, Sanika, Newton, Schalon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995174/
https://www.ncbi.nlm.nih.gov/pubmed/35418743
http://dx.doi.org/10.2147/OPTH.S358847
_version_ 1784684257741897728
author Dhaliwal, Deepinder K
Chirikov, Viktor
Schmier, Jordana
Rege, Sanika
Newton, Schalon
author_facet Dhaliwal, Deepinder K
Chirikov, Viktor
Schmier, Jordana
Rege, Sanika
Newton, Schalon
author_sort Dhaliwal, Deepinder K
collection PubMed
description PURPOSE: To assess the incremental burden of corneal transplant surgery for US commercially insured patients with Fuchs endothelial corneal dystrophy (FECD) treated with endothelial keratoplasty (EK) compared to controls. METHODS: The study design was retrospective cohort using IBM(®) MarketScan(®) claims (January 2014–September 2019) and included EK-treated (N=1562) and control patients (N=23,485) having ≥12 months’ enrollment before and after diagnosis, who were subsequently matched on select characteristics. The index date was the beginning of the pre-operative period (3 months before EK); synthetic EK index was assigned for controls. All-cause, eye-disease, and complication-related healthcare resource utilization (HCRU) and costs were compared up to 36 months post index. For a small subset of patients, patient data were linked to the Health and Productivity Management supplemental database, which integrates data on productivity loss and disability payments. RESULTS: Matched cohorts included 804 EK-treated and 1453 controls with average age 65.7 years, 1383 (61%) female. Over 12 months of follow-up, all-cause ($41,199 vs $20,222, p<0.001) and eye-disease related costs ($22,951 vs $1389, p<0.001) were higher among EK-treated patients than controls. The cost differential increased additionally by $1000–$2000 per annum by 36 months of follow-up. While balanced at baseline, over follow-up EK-treated patients had higher prevalence of glaucoma, elevated intraocular pressure, cataract, cataract surgery, diagnosis of cornea transplant rejection, retinal edema. By 36 month of follow-up, EK-treated patients had 9 more short-term disability days, resulting in $2992 additional burden of disability payments. CONCLUSION: This study found a higher cost burden among FECD patients receiving EK treatment versus those who did not. With a shift in management of FECD, cost burden estimates generated in this study could serve as an important benchmark for future studies.
format Online
Article
Text
id pubmed-8995174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89951742022-04-12 Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019) Dhaliwal, Deepinder K Chirikov, Viktor Schmier, Jordana Rege, Sanika Newton, Schalon Clin Ophthalmol Original Research PURPOSE: To assess the incremental burden of corneal transplant surgery for US commercially insured patients with Fuchs endothelial corneal dystrophy (FECD) treated with endothelial keratoplasty (EK) compared to controls. METHODS: The study design was retrospective cohort using IBM(®) MarketScan(®) claims (January 2014–September 2019) and included EK-treated (N=1562) and control patients (N=23,485) having ≥12 months’ enrollment before and after diagnosis, who were subsequently matched on select characteristics. The index date was the beginning of the pre-operative period (3 months before EK); synthetic EK index was assigned for controls. All-cause, eye-disease, and complication-related healthcare resource utilization (HCRU) and costs were compared up to 36 months post index. For a small subset of patients, patient data were linked to the Health and Productivity Management supplemental database, which integrates data on productivity loss and disability payments. RESULTS: Matched cohorts included 804 EK-treated and 1453 controls with average age 65.7 years, 1383 (61%) female. Over 12 months of follow-up, all-cause ($41,199 vs $20,222, p<0.001) and eye-disease related costs ($22,951 vs $1389, p<0.001) were higher among EK-treated patients than controls. The cost differential increased additionally by $1000–$2000 per annum by 36 months of follow-up. While balanced at baseline, over follow-up EK-treated patients had higher prevalence of glaucoma, elevated intraocular pressure, cataract, cataract surgery, diagnosis of cornea transplant rejection, retinal edema. By 36 month of follow-up, EK-treated patients had 9 more short-term disability days, resulting in $2992 additional burden of disability payments. CONCLUSION: This study found a higher cost burden among FECD patients receiving EK treatment versus those who did not. With a shift in management of FECD, cost burden estimates generated in this study could serve as an important benchmark for future studies. Dove 2022-04-06 /pmc/articles/PMC8995174/ /pubmed/35418743 http://dx.doi.org/10.2147/OPTH.S358847 Text en © 2022 Dhaliwal et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Dhaliwal, Deepinder K
Chirikov, Viktor
Schmier, Jordana
Rege, Sanika
Newton, Schalon
Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title_full Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title_fullStr Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title_full_unstemmed Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title_short Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014–2019)
title_sort cost burden of endothelial keratoplasty in fuchs endothelial dystrophy: real-world analysis of a commercially insured us population (2014–2019)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995174/
https://www.ncbi.nlm.nih.gov/pubmed/35418743
http://dx.doi.org/10.2147/OPTH.S358847
work_keys_str_mv AT dhaliwaldeepinderk costburdenofendothelialkeratoplastyinfuchsendothelialdystrophyrealworldanalysisofacommerciallyinsureduspopulation20142019
AT chirikovviktor costburdenofendothelialkeratoplastyinfuchsendothelialdystrophyrealworldanalysisofacommerciallyinsureduspopulation20142019
AT schmierjordana costburdenofendothelialkeratoplastyinfuchsendothelialdystrophyrealworldanalysisofacommerciallyinsureduspopulation20142019
AT regesanika costburdenofendothelialkeratoplastyinfuchsendothelialdystrophyrealworldanalysisofacommerciallyinsureduspopulation20142019
AT newtonschalon costburdenofendothelialkeratoplastyinfuchsendothelialdystrophyrealworldanalysisofacommerciallyinsureduspopulation20142019